Want to join the conversation?
$BIIB 2Q15 PR: FY15 Guidance: Revenue growth expected to be approx. 6-8% vs. 2014, a decrease from prior guidance based largely on revised expectations for the growth of TECFIDERA; R&D expense approx. 19-20% of total revenue; SG&A expense approx. 20-21% of total revenue; GAAP diluted EPS between $14.25-14.70.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.